Latest Going Concern News

Harris Technology Group Limited reported an 18.9% increase in half-year revenue to $8.3 million, turning a modest profit after a prior loss, while flagging ongoing financial uncertainties linked to upcoming debt repayments.

FortifAI Limited reported a 51% revenue decline but a 70% reduction in net loss for H1 FY26, alongside completing a major AI technology acquisition and securing $5 million in fresh capital.

Oliver’s Real Food Limited has reported a statutory net profit after tax of $995,000 for the half-year ended December 2025, marking a $1.82 million turnaround from the previous loss. This improvement comes despite a 6.5% revenue decline, driven by strategic store closures and disciplined cost management.

Global Health Limited reports a modest half-year loss reduction alongside a steady rise in recurring SaaS revenue, signaling progress in its digital healthcare transformation.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.

Carnegie Clean Energy reported a $1.7 million loss for the half-year ending December 2025, while pushing forward with key wave energy projects and securing $2.1 million in fresh capital.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.

Compumedics Limited has reported a robust half-year performance, with revenue climbing 32% to $31 million and a return to profitability, driven by strong MEG system sales and SaaS growth.

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

Wagners Holding Company Limited has reported a robust half-year result for December 2025, with revenue climbing to $251.7 million and net profit after tax soaring 70% to $21 million. Improved margins and operational efficiencies across key segments underpin the strong performance.